Comparison of Anti Thyroid Drugs, Radioactive Iodine and Surgery for Graves’ Disease: A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.66266/inajemd.v1i2.12Keywords:
Thyroid hormone, hyperthyroid, methimazole, iodineAbstract
Selection of therapy for Graves’ Disease (GD) has always been a puzzling decision to be taken by both the patient and physician. This is due to the three modalities (Anti Thyroid Drug (ATD), Radioactive Iodine (RAI) and surgery) in with each one being just as established as the other two in being an effective treatment strategy. Therefore, this study was conducted in purpose to compare ATD, RAI and surgery for GD. The author searches from several databases such as PubMed, Directory of Open Access Journals (DOAJ), and Science Direct as well as registers, such as Cochrane Central Register of Controlled Trials (CENTRAL). The systematic review was incorporated to all of seven studies and six studies has been selected to be included in the analysis. ATD has higher risk of relapse compared to RAI (RR 2.77, 95% CI 0.99–7.75); p=0.05) and surgery (RR 6.60, 95% CI 3.76–11.58); p<0.00001). In comparison to surgery, RAI has higher risk of relapse (RR 2.52, 95% CI 0.66–9.67); p 0.18). ATD has lower success rate compared to RAI (RR 0.47, 95% CI 0.35–0.63); p<0.00001) and surgery (RR 0.44, 95% CI 0.34–0.58); p<0.00001). ATD has lower risk of hypothyroid compared to RAI (RR 0.08, 95% CI 0.02–0.27); p<0.0001) and surgery (RR 0.09, 95% CI 0.02–0.40); p=0.001). ATD has the highest risk of relapse compared to RAI and surgery. RAI and surgery did not differ significantly in risk of relapse and hypothyroid.
Downloads
References
1. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association. Am Asso of Clin Endocrinol. Thyroid. 2011;21(6):593-646.
2. Davies TF. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J of Clin Invest. 2005;115(8).
3. Girgis CM, Champion BL, Wall JR. Current concepts in graves' disease. Ther Adv Endocrinol Metab. 2011 Jun;2(3):135-44
4. Okosieme OE, Taylor PN, Evans C, Thayer D, Chai A, Khan I, et al. Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lanc Diab Endocrinol. 2019;7(4).
5. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. Am Thyr Asso Guid for Diag and Manag of Hyperthyroid and Oth Caus of Thyrotoxic. Thyr. 2016;26(10):1343-1421.
6. Abraham-Nordling M, Törring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, et al. Graves’ Disease: A Long-Term Quality-of-Life Follow Up of Patients Randomized to Treatment with Antithyroid Drugs, Radioiodine, or Surgery. Thyroid. 2005;15(11).
7. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and Similarities in the Diagnosis and Treatment of Graves’ Disease in Europe, Japan, and The United States. Thyroid. 1991;1(2).
8. Burch HB, Burman KD, Cooper DS. A 2011 Survey of Clinical Practice Patterns in the Management of Graves’ Disease. J Clin Endocrinol Metab. 2012;97(12).
9. Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH. J Clin Endocrinol Metab. 2017;102(7).
10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71
11. Wells G, Shea B, O’Connell D, Robertson J, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
12. Conaglen HM, Tamatea JAU, Conaglen J V., Elston MS. Treatment choice, satisfaction and quality of life in patients with Graves’ disease. Clin Endocrinol (Oxf). 2018;88(6):977–84.
13. Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative Effectiveness of Treatment Choices for Graves’ Hyperthyroidism: A Historical Cohort Study. Thyroid. 2017;27(4):497–505.
14. Sjölin G, Holmberg M, Törring O, Byström K, Khamisi S, De Laval D, et al. The Long-Term Outcome of Treatment for Graves’ Hyperthyroidism. Thyroid. 2019;29(11):1545–57.
15. Brito JP, Payne S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, et al. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves’ Disease: A Nationwide Population-Based Study. Thyroid. 2020;30(3):357–64.
16. Berglund J, Christensen Sb, Dymling Jf, Hallengren B. The incidence of recurrence and hypothyroidism following treatment with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis in Malmö during the period 1970–1974. J Intern Med. 1991;229(5):435–42.
17. Leary AC, Grealy G, Higgins TM, Buckley N, Barry G, Murphy D, et al. Long term outcomes of treatment of hyperthyroidism 47 Long-term Outcomes of Treatment of Hyperthyroidism in Ireland. J Med Sc. 1999;168(1).
18. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4).
19. National Institute for Health and Care Excellence. Thyroid disease: assessment and management. Un Kingd; 2019 Nov.
20. Azizi F, Abdi H, Mehran L, Amouzegar A. Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves’ disease: a systematic scoping review. J Endocrinol Invest. 2022;45(6).
21. Jeong YA, Yoon JH, Kim HK, Kang HC. Graves’ Disease Patients with Large Goiters Respond Best to Radioactive Iodine Doses of at Least 15 mCi: a Sonographic Volumetric Study. Int J of Thyr. 2018;11(2).
22. Karyampudi A, Hamide A, Halanaik D, Sahoo J, Kamalanathan S. Radioiodine therapy in patients with Graves′ disease and the effects of prior carbimazole therapy. Indian J Endocrinol Metab. 2014;18(5).
23. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. Relation between Therapy for Hyperthyroidism and the Course of Graves’ Ophthalmopathy. New Eng J of Med. 1998;338(2).
24. Ross DS. Radioiodine Therapy for Hyperthyroidism. New Eng J of Med. 2011;364(6).
25. Guo Z, Yu P, Liu Z, Si Y, Jin M. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves' diseases: a meta-analysis of randomized clinical trials. Clin
Downloads
Published
Issue
Section
License
Copyright (c) 2024 InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright and grant the Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD) the right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
© Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD). Published by the Indonesian Society of Endocrinology (PERKENI).
